UK Parkinson’s Disease Treatment Market Size & Outlook

The parkinson’s disease treatment market in UK is expected to reach a projected revenue of US$ 484.2 million by 2030. A compound annual growth rate of 7.5% is expected of UK parkinson’s disease treatment market from 2025 to 2030.
Revenue, 2024 (US$M)
$317.2
Forecast, 2030 (US$M)
$484.2
CAGR, 2025 - 2030
7.5%
Report Coverage
UK

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

UK parkinson’s disease treatment market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Related Markets

UK parkinson’s disease treatment market highlights

  • The UK parkinson’s disease treatment market generated a revenue of USD 317.2 million in 2024 and is expected to reach USD 484.2 million by 2030.
  • The UK market is expected to grow at a CAGR of 7.5% from 2025 to 2030.
  • In terms of segment, carbidopa-levodopa was the largest revenue generating drug class in 2024.
  • Carbidopa-Levodopa is the most lucrative drug class segment registering the fastest growth during the forecast period.


Parkinson’s disease treatment market data book summary

Market revenue in 2024USD 317.2 million
Market revenue in 2030USD 484.2 million
Growth rate7.5% (CAGR from 2025 to 2030)
Largest segmentCarbidopa-levodopa
Fastest growing segmentCarbidopa-Levodopa
Historical data2018 - 2023
Base year2024
Forecast period2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationCarbidopa-Levodopa, Dopamine Agonist, MAO-B Inhibitors, COMT inhibitors, Anticholinergics
Key market players worldwideNovartis AG ADR, Teva Pharmaceutical Industries Ltd, Merck & Co Inc, GSK PLC, AbbVie Inc, H. Lundbeck AS Class A, Supernus Pharmaceuticals Inc, Amneal Pharmaceuticals Inc Ordinary Shares - Class A, Cerevel Therapeutics Holdings Inc Ordinary Shares


Other key industry trends

  • In terms of revenue, UK accounted for 5.6% of the global parkinson’s disease treatment market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, UK parkinson’s disease treatment market is projected to lead the regional market in terms of revenue in 2030.
  • UK is the fastest growing regional market in Europe and is projected to reach USD 484.2 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Parkinson’s Disease Treatment Market Companies

Name Profile # Employees HQ Website
Amneal Pharmaceuticals Inc Ordinary Shares - Class A View profile 7700 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, United States, 08807 https://www.amneal.com
Cerevel Therapeutics Holdings Inc Ordinary Shares View profile 355 222 Jacobs Street, Suite 200, Cambridge, MA, United States, 02141 https://www.cerevel.com
Supernus Pharmaceuticals Inc View profile 652 9715 Key West Avenue, Rockville, MD, United States, 20850 https://www.supernus.com
H. Lundbeck AS Class A View profile 5700 Ottiliavej 9, Valby, Denmark, 2500 https://www.lundbeck.com
GSK PLC View profile 70200 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS https://www.gsk.com
Merck & Co Inc View profile 72000 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 https://www.merck.com
AbbVie Inc View profile 50000 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 http://www.abbvieinvestor.com
Teva Pharmaceutical Industries Ltd View profile 37851 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 https://www.tevapharm.com
Novartis AG ADR View profile 76057 Lichtstrasse 35, Basel, Switzerland, 4056 https://www.novartis.com

UK parkinson’s disease treatment market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to parkinson’s disease treatment market will help companies and investors design strategic landscapes.


Carbidopa-levodopa was the largest segment with a revenue share of 27.08% in 2024. Horizon Databook has segmented the UK parkinson’s disease treatment market based on carbidopa-levodopa, dopamine agonist, mao-b inhibitors, comt inhibitors, anticholinergics covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to UK parkinson’s disease treatment market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of UK parkinson’s disease treatment market databook

  • Our clientele includes a mix of parkinson’s disease treatment market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the UK parkinson’s disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into UK parkinson’s disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

UK parkinsons disease treatment market size, by drug class, 2018-2030 (US$M)

UK Parkinson’s Disease Treatment Market Outlook Share, 2024 & 2030 (US$M)

UK parkinsons disease treatment market size, by drug class, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online